HKG · Financial Statements

Shanghai Henlius Biotech, Inc. (2696.HK) Financial Statements

$50.75 HKG: 2696.HK Market Cap $27.67B

Full income statement, balance sheet, and cash flow statement for Shanghai Henlius Biotech, Inc. (2696.HK), plus valuation and return ratios.

Annual financials are not yet available for this stock.

Valuation & Return Ratios

MetricValue
PEG Ratio2.85
EV / EBITDA25.12
FCF Yield—
Quick Ratio0.57
Interest Coverage—
Return 1Y-33.00%
Return 3Y393.68%
Return 5Y149.12%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
2696.HK Overview 2696.HK Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.